TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02269163

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Immune Globulin Intravenous
Description: Gammargard, Gammaplex,Gamunex, or Octogam IGIV Product

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prometic's Immune Globulin Intravenous 10%
Description: Liquid formulation of Prometic Immune Globulin Intravenous 10% (human) in 50 mL vials containing 100 mg/mL of immunoglobulin G (IgG)
Study: NCT02753491

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational short interview
Description: New designed motivational short interview model
Study: NCT02440022

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Lutonix DCB

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Balloon Angioplasty Catheter

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Transluminal Angiography
Description: Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a balloon at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Transluminal Angiography
Description: Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a balloon at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.
Study: NCT02843594

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LEEP intervention
Description: Low Energy Endosafe Phaco (LEEP) with micro-interventional lens fragmentation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LEEP intervention
Description: Low Energy Endosafe Phaco (LEEP) with micro-interventional lens fragmentation

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard Phaco Control
Study: NCT04413864

Intervention type: OTHER
Group type: OTHER
Intervention: Inflammatory cytokines and chemokines profiles of patients with dexmedetomidine administration
Description: Assigned Interventions:~* Blood samples collection at inclusion (D0) and follow-up visits (D2, D7 and M6)~* CAM-ICU scores during ICU hospitalisation, neurological questionnaires at M6 (GOAT, GOSE, MOCA, Barthel Index, PTSD, GDS, Rankin score, HADS)
Study: NCT02252718

Intervention type: OTHER
Intervention: Stool Assessment
Description: After passing a stool by the child participating in the study, within a short-time interval (\<5 min), the stool will be assessed independently by one of the parents and the medical doctor. At the same time a parent will take 2 photos with phone photographic camera. Then the photographs will be independently evaluated by another doctor who will be unaware of both the in vivo stool appraisal and child condition.
Study: NCT01996943

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethanol
Description: 6% volume/volume ethanol in 0.45% saline solution.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo with be 0.45% saline solution (half normal saline).
Study: NCT00001258

Intervention type: DRUG
Intervention: Oxygen-15 Water
Study: NCT03381781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: 20mg/m\^2,d1-5,ivgtt,28days as a duration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic Trioxide
Description: 0.16mg/kg,d1-5,ivgtt,28days as a duration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 15mg/m\^2,hypodermic injection,q12h,d1-7
Study: NCT01581372

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacist care
Description: Pharmacist prescribing, education, drug management
Study: NCT02402569

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 32 channels Deep Brain Stimulator

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 32 channels Deep Brain Stimulator
Study: NCT01582867

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARTIS hemodialysis system
Description: Software versions:~Control Product: 8.06.01KA. Study Product: 8.06.01B_HC01

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARTIS hemodialysis system
Description: Software versions:~Control Product: 8.06.01KA. Study Product: 8.06.01B_HC01
Study: NCT04819581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-103
Description: lidocaine topical system 5.4%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-103
Description: lidocaine topical system 5.4%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-103
Description: lidocaine topical system 5.4%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZTlido
Description: lidocaine topical system 1.8%
Study: NCT03371927

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SINC Feeding Protocol
Description: Safe individualized nipple-feeding competence protocol for premature infants
Study: NCT04582604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: modified By/Cy conditioning regimen intensified by Ruxolitinib and Decitabine
Description: Day -15 to -14 ： Decitabine 20 mg/m2/day, Ruxolitinib 70mg bid; Day-10： Cytarabine 1.6 g/m2/day CI (only for Haploidentical and unrelated donor), Ruxolitinib 60mg bid; Day- 9： Cytarabine 4g/m2/day CI, Ruxolitinib 60mg bid; Day- 8 to -7： Busulfan 0.8mg/kg Q6h iv, Ruxolitinib 50mg bid; Day-6: Busulfan 0.8mg/kg Q6h iv, Ruxolitinib 40mg bid; Day-5： Cyclophosphamide 1.8 g/m2/day CI, Ruxolitinib 30mg bid; Day-4： Cyclophosphamide 1.8 g/m2/day CI, Ruxolitinib 20mg bid; Day-3： Carmustine 250mg/m2/day iv, Ruxolitinib 10mg bid; Day-2： Ruxolitinib 5mg bid; Day-1： Ruxolitinib 5mg qd;
Study: NCT01697904

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Titration of oxygen during newborn resuscitation in delivery room

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Titration of oxygen during newborn resuscitation in delivery room
Study: NCT00635440

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: neuromuscular electrical stimulation: Cefar-Sport (CefarCompex Scandinavia AB)
Description: Electrical stimuli of 50 Hz (pulse width 0.25ms, 8 sec on, 4 sec off) were applied daily for 30 min, for 4 days, starting on the first postoperative day.The amplitude of the electrical stimuli in the stimulated leg was adjusted to ensure maximum tolerable muscle contraction.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: neuromuscular electrical stimulation: Cefar-Sport (CefarCompex Scandinavia AB)
Description: Electrical stimuli of 50 Hz (pulse width 0.25ms, 8 sec on, 4 sec off) were applied daily for 30 min, for 4 days, starting on the first postoperative day. Current was increased until the patient could feel a tingling sensation but no muscle contraction was visible or palpable.
Study: NCT04203940

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cyanoacryale
Description: mesh fixation was done using dots of N-butyl 2-cyanoacrylate tissue glue

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suture
Description: mesh fixation was done with polypropylene 2/0 sutures
Study: NCT04054102

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robot and tDCS on-line
Description: Combined transcranial direct current stimulation(tDCS) on-line and upper extremity rehabilitation robot for 5 times a week for 4 weeks

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Robot and sham tDCS
Description: Combined sham tDCS and upper extremity rehabilitation robot for 5 times a week for 4 weeks
Study: NCT01914783

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ultrafine particles
Description: exposure to ultrafine particles

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ultrafine particles and ozone
Description: exposure to ultrafine particles and ozone

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: clean air
Description: Exposure to clean air.
Study: NCT02321683

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Taperloc
Description: Femoral stem with electrochemical deposition of hydroxyapatite

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Taperloc
Description: Femoral stem with electrochemical deposition of hydroxyapatite
Study: NCT01635036

Intervention type: DEVICE
Intervention: In-vitro fertilization using Eeva
Description: Eeva will image embryos through cleavage stage (Day 3). Embryologists will use Eeva results along with traditional morphological grading to assist in selecting embryo(s) for transfer or freezing.
Study: NCT03198104

Intervention type: DEVICE
Intervention: MRI

Intervention type: DEVICE
Intervention: MRI

Intervention type: DEVICE
Intervention: MRI
Study: NCT00778713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets
Study: NCT02629536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine 600 mg, VitE 250 IU, VitC 500 mg tablet
Description: N-acetyl cysteine 600 mg, VitE 250 IU, VitC 500 mg tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: N-acetyl cysteine 600 mg, VitE 250 IU, VitC 500 mg tablet
Description: N-acetyl cysteine 600 mg, VitE 250 IU, VitC 500 mg tablet
Study: NCT01611298

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus
Description: Stem cell transplant donors will receive one dose of tetanus toxoid 0.5mL intramuscularly into deltoid or medial lateral thigh 7-10 days prior to bone marrow or peripheral blood stem cell harvest.~Stem cell transplant recipients will receive one dose of tetanus toxoid 0.5mL intramuscularly (or subcutaneously if platelet count less than 50,000/uL) into deltoid or medial lateral thigh 7-10 days prior to stem cell transplant (FIRST dose).~Stem cell transplant recipients will receive a subsequent dose of tetanus toxoid 0.5mL given intramuscularly into deltoid or medial lateral thigh (or given subcutaneously if platelet count is less than 50,000/uL) approximately 3 months following allo stem cell transplant. Patients must meet re-evaluation criteria to receive injection.
Study: NCT04324086

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide with XP-endo Finisher file
Description: XP-endo Finisher files (FKG Dentaire, La Chaux-de-Fonds, Switzerland). file will be used with an endodontic motor X-Smart (Dentsply Sirona, Ballaigues, Switzerland) in removal of calcium hydroxide

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide with Irrisafe Ultrasonic tip
Description: passive ultrasonic irrigation (PUI) with an IrriSafe Ultrasonic tips (Acteon,France), which will be driven by an ultrasonic device (Newtron P5, Satelec, Acteongroup, Merignac, France) in reemoval of calcium hydroxide

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Calcium hydroxide with side vented needle
Description: conventional syringe irrigation with side vented needle (prime Dent, India) in removal of calcium hydroxide
Study: NCT00493480

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carvedilol
Description: 6.25 mg of carvedilol for 12 weeks, to achieve a satisfactory pulse reduction the doses are doubled weekly up to a maximum of 25 mg carvedilol daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propranolol
Description: 80 mg of propranolol for 12 weeks, to achieve a satisfactory pulse reduction the doses are doubles weekly up to a maximum of 360 mg propranolol daily
Study: NCT00841672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren/amlodipine 300/10 mg tablet
Description: Each dose was taken by mouth with water at approximately 8:00 in the morning with or without food, except on the morning of the next office/clinic visit, when the medication was taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of two tablets and one capsule of study medication per day throughout the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine 10 mg capsule
Description: Each dose was taken by mouth with water at approximately 8:00 in the morning with or without food, except on the morning of the next office/clinic visit, when the medication was taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of two tablets and one capsule of study medication per day throughout the study.
Study: NCT02770677

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Dantien Salee Yoga Training Program
Description: The intervention aims to improve pulmonary function and functional fitness.
Study: NCT02649985

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: [F-18]PBR06
Description: PET radiopharmaceutical

Intervention type: DRUG
Group type: OTHER
Intervention: [F-18]PBR06
Description: PET radiopharmaceutical

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [F-18]PBR06
Description: PET radiopharmaceutical

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [F-18]PBR06
Description: PET radiopharmaceutical

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [F-18]PBR06
Description: PET radiopharmaceutical

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [C-11]PBR28
Description: PET radiopharmaceutical
Study: NCT01781741

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: therapeutic lymphadenectomy (TEMLA) and Stereotactic Body radiation therapy (SBRT)
Description: Undergo TEMLA and SBRT
Study: NCT02077803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin, 100 mg
Description: Each tablet contains canagliflozin (CANA) of 100 mg to be taken orally (by mouth).
Study: NCT01014767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Standard Arm, Cycle 2: 350 mg/m2 IV over 2 hours on day 2 and 3~All Arms, Cycles 4 \& 6: 350 mg/m2 IV over 2 hours on day 2 and 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Standard Arm, Cycle 2: 350 mg/m2 IV over 2 hours on day 2 and 3~All Arms, Cycles 4 \& 6: 350 mg/m2 IV over 2 hours on day 2 and 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Standard Arm, Cycle 2: 350 mg/m2 IV over 2 hours on day 2 and 3~All Arms, Cycles 4 \& 6: 350 mg/m2 IV over 2 hours on day 2 and 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Standard Arm, Cycle 2: 350 mg/m2 IV over 2 hours on day 2 and 3~All Arms, Cycles 4 \& 6: 350 mg/m2 IV over 2 hours on day 2 and 3
Study: NCT02077803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin XR, 500 mg
Description: Each tablet contains metformin extended release (MET XR), 500 mg, to be taken orally (by mouth).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CANA/MET XR FDC, Formulation 1, 50 mg/1000 mg
Description: Each tablet contains 50 mg of canagliflozin and 1000 mg of metformin HCl granulate, formulation 1, to be taken orally.
Study: NCT06516081

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Micronutrient powder (Sprinkles®)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Micronutrient powder (Sprinkles®)
Study: NCT04345484

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal-management training
Description: 9-week goal-management program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Healthy Lifestyle Program
Study: NCT02869542

Intervention type: OTHER
Intervention: Data collection
Study: NCT00285805

Intervention type: DRUG
Group type: OTHER
Intervention: Rosiglitazone versus placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Rosiglitazone versus placebo

Intervention type: DRUG
Group type: OTHER
Intervention: response (sodium excretion) to amiloride infusion

Intervention type: DRUG
Group type: OTHER
Intervention: response (sodium excretion) to amiloride infusion

Intervention type: DRUG
Group type: OTHER
Intervention: response (sodium excretion) to furosemide infusion

Intervention type: DRUG
Group type: OTHER
Intervention: response (sodium excretion) to furosemide infusion
Study: NCT03978000

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IBP-9414
Description: Oral suspension

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile water
Study: NCT02563743

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem-solving based intervention
Description: The intervention comprises both the employee and the employer, and follows a clear structure comprising problem solving, stepwise activation and relapse prevention. It includes three meetings at the OHS with additional follow-ups.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Study participants that are randomized into the control group will receive the usual care given at the OHS. This intervention will differ due to differences between the OHS units.
Study: NCT03408483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quadratus Lumborum Block (QLB)
Description: Under ultrasound guidance, the needle will be advanced to the posterior border of the quadratus lumborum muscle. After negative aspiration, a bolus of 40 mL of 0.25% bupivacaine with 1:400,000 epinephrine will be injected in 5 mL aliquots, ensuring proper placement of needle tip and appropriate spread of local anesthetic.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: This is currently the standard of care, no local anesthetic will be injected. Pain will be managed with parenteral and oral medication.
Study: NCT03799731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM102
Description: GM102 7 mg/kg weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM102
Description: GM102 7 mg/kg weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine/Tipiracil
Description: Lonsurf 35 mg/m² twice daily during 10 days per cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine/Tipiracil
Description: Lonsurf 35 mg/m² twice daily during 10 days per cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM102 expansion
Description: GM102 7 mg/kg weekly after a loading dose of 10 mg/kg q1w during 28-day cycle 1
Study: NCT04688957

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: oseodensification sinus lifting
Description: application of first densah bur with densifying mood (reverse) counterclockwise, 1200 revolution per minute until the sinus is reached then use a wider densah bur with the same mode and bouncing motion to elevate the sinus floor up to 3 mm in 1mm increments.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: osteotome sinus lifting
Description: drilling implant site with consecutive drills short of the sinus floor by 1-2mm , using osteotome in appropriate size and application of one tap until sinus floor is elevated, using the final drill for the desired implant diameter
Study: NCT02250781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral ONC201
Description: Given PO
Study: NCT02041884

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iCBT for Adults with ADHD
Description: A skill training internet-based treatment program based on CBT and DBT interventions .

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet stress-reduction
Description: Internet-based psychoeducation, stress-reduction, and Applied Relaxation based on CBT (control group)

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as usual (TAU)/waiting list
Description: Treatment as usual (usually medications for ADHD), will be offered treatment after the FU3 (week 24)
Study: NCT03862222

Intervention type: OTHER
Intervention: Retinal Imaging
Description: Retinal imaging will be conducted on the Heidelberg SPECTRALIS (FDA 510k cleared) device, routinely used in clinical care in ophthalmology. Optical Coherence Tomography (OCT) and Angiography (OCT-A) sequences will be conducted, as well as a sequence examining macular pigment (MPOD).

Intervention type: OTHER
Intervention: Retinal Imaging
Description: Retinal imaging will be conducted on the Heidelberg SPECTRALIS (FDA 510k cleared) device, routinely used in clinical care in ophthalmology. Optical Coherence Tomography (OCT) and Angiography (OCT-A) sequences will be conducted, as well as a sequence examining macular pigment (MPOD).

Intervention type: OTHER
Intervention: Retinal Imaging
Description: Retinal imaging will be conducted on the Heidelberg SPECTRALIS (FDA 510k cleared) device, routinely used in clinical care in ophthalmology. Optical Coherence Tomography (OCT) and Angiography (OCT-A) sequences will be conducted, as well as a sequence examining macular pigment (MPOD).

Intervention type: OTHER
Intervention: Retinal Imaging
Description: Retinal imaging will be conducted on the Heidelberg SPECTRALIS (FDA 510k cleared) device, routinely used in clinical care in ophthalmology. Optical Coherence Tomography (OCT) and Angiography (OCT-A) sequences will be conducted, as well as a sequence examining macular pigment (MPOD).
Study: NCT02318901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ado-trastuzumab emtansine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Study: NCT01595334

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetrorelix
Description: Cetrorelix 0.25 mg/d would be administered by subcutaneous injection to women when the plasma LH is higher (\>4.5 mIU/ml) in the study arm

Intervention type: DRUG
Group type: OTHER
Intervention: Luprolide Acetate
Description: Women in the control arm would receive Luprolide acetate 1 mg/day by subcutaneous injection
Study: NCT04124042

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XT-150
Description: plasmid DNA

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XT-150
Description: plasmid DNA

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XT-150
Description: plasmid DNA

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XT-150
Description: plasmid DNA

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: XT-150
Description: plasmid DNA

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: XT-150
Description: plasmid DNA

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a sterile phosphate-buffered saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a sterile phosphate-buffered saline